Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Innsbruck Medical University, Innsbruck, Austria.
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):578-588. doi: 10.1016/S2468-1253(21)00020-0. Epub 2021 May 4.
Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, the predominant cause of mortality in people with NAFLD), chronic kidney disease, and some types of extrahepatic malignancies. The magnitude of this risk parallels the severity of NAFLD (especially the stage of liver fibrosis). There are probably multiple underlying mechanisms by which NAFLD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications. Addressing the growing burden of NAFLD will require setting up a multidisciplinary working group and framework to progress and embrace novel collaborative ways of working to deliver holistic, person-centred care and management of people with NAFLD.
非酒精性脂肪性肝病(NAFLD)是一个全球性的公共卫生问题。本综述概述了目前的文献,以支持 NAFLD 是一种多系统疾病的观点。令人信服的证据表明,NAFLD 与多种肝外并发症(如 2 型糖尿病、心血管疾病(即 NAFLD 患者的主要死亡原因)、慢性肾脏病和某些类型的肝外恶性肿瘤)的发病风险之间存在很强的关联。这种风险的程度与 NAFLD 的严重程度(尤其是肝纤维化的阶段)相平行。NAFLD 可能通过多种潜在机制增加心血管疾病、2 型糖尿病和肝外并发症的风险。为了应对日益增长的 NAFLD 负担,需要建立一个多学科工作组和框架,以推进并接受新颖的合作工作方式,为 NAFLD 患者提供整体的、以患者为中心的护理和管理。